TY - JOUR
T1 - A Combined Sulbactam/Cefoperazone And Amikacin Therapy For The Treatment Of Infections Complicated With Hematological Deseases
AU - Takashima, Teruyuki
AU - Tsuda, Shoichiro
AU - Misawa, Shinichi
AU - Horiike, Shigeo
AU - Kuzuyama, Yuko
AU - Hirakawa, Kouichi
AU - Nakai, Hiroyuki
AU - Seriu, Taku
AU - Tanaka, Shinji
AU - Nishida, Kazuhiro
AU - Taniwaki, Masafumi
AU - Kashima, Kei
AU - Fujii, Hiroshi
AU - Nakagawa, Hitoshi
AU - Nakai, Tetsuro
AU - Ohkawara, Yasuo
AU - Imanishi, Hitoshi
AU - Nishigaki, Hikari
AU - Yokota, Shouhei
PY - 1993
Y1 - 1993
N2 - Eightysix patients with infections associated with hematological disorders were treated with sulbactam/cefoperazone (SBT/CPZ) and amikacin (AMK). Among 71 evaluable cases, 30 cases had acute non-lymphocytic leukemia, 3 acute lymphoblastic leukemia, 25 malignant lymphoma, and 7 myelodysplastic syndrome as underlying diseases. Excellent responses were obtained in 33 cases (46.5%) and good responses in 14 cases (19.7%), with an overall efficacy rate of 66.2%. The efficacy rate among cases with suspected sepsis was 72.5%. This treatment was also effective in 69.2% of cases in which neutrophil counts were less than 500//A through the course of administration. The eradication rate was 83.3% among 6 strains in which Gram-negative rods were detected. Side effects were minimum; skin rash in 1 case, slight elevation of APTT in 3 and slight elevation of total bilirubin in 1. Thus, this combination antibacterial chemotherapy is an effective and safe regimen for the treatment of severe infections in patients with hematological disorders.
AB - Eightysix patients with infections associated with hematological disorders were treated with sulbactam/cefoperazone (SBT/CPZ) and amikacin (AMK). Among 71 evaluable cases, 30 cases had acute non-lymphocytic leukemia, 3 acute lymphoblastic leukemia, 25 malignant lymphoma, and 7 myelodysplastic syndrome as underlying diseases. Excellent responses were obtained in 33 cases (46.5%) and good responses in 14 cases (19.7%), with an overall efficacy rate of 66.2%. The efficacy rate among cases with suspected sepsis was 72.5%. This treatment was also effective in 69.2% of cases in which neutrophil counts were less than 500//A through the course of administration. The eradication rate was 83.3% among 6 strains in which Gram-negative rods were detected. Side effects were minimum; skin rash in 1 case, slight elevation of APTT in 3 and slight elevation of total bilirubin in 1. Thus, this combination antibacterial chemotherapy is an effective and safe regimen for the treatment of severe infections in patients with hematological disorders.
UR - http://www.scopus.com/inward/record.url?scp=0027281316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027281316&partnerID=8YFLogxK
U2 - 10.11553/antibiotics1968b.46.251
DO - 10.11553/antibiotics1968b.46.251
M3 - Article
C2 - 8510322
AN - SCOPUS:0027281316
SN - 0368-2781
VL - 46
SP - 251
EP - 258
JO - Japanese Journal of Antibiotics
JF - Japanese Journal of Antibiotics
IS - 3
ER -